Tecentriq 1,200 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEE1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,467
Award facts
- Contract value 100% obligated
- $41,466.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $41,466.72 to DMS Pharmaceutical Group Inc. for the supply of Tecentriq (1,200 mg/20 ml vials). The award was issued on January 6, 2026, with an ultimate completion date of January 28, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order will be performed at the vendor's Park Ridge location and represents part of the company's ongoing pharmaceutical supply operations supporting Department of Defense medical requirements.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion government-wide acquisition strategy. The parent IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical regional pharmaceutical supplier for military healthcare facilities worldwide. The company's extensive product portfolio includes oncology treatments, immunosuppressants, biologics, vaccines, and specialty pharmaceuticals, supporting the diverse medical supply needs of the Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DR26FMEE1?
SPE2DR26FMEE1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FMEE1 worth?
The government has obligated $41,467 on SPE2DR26FMEE1.
Is contract SPE2DR26FMEE1 an order under another contract?
Yes. SPE2DR26FMEE1 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEE1 competed?
The extent of competition for SPE2DR26FMEE1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award